Asset profile
omilancor
Small molecule
Evidence outlook
No featureable registry evidence
The studies registered under this drug are withdrawn, terminated, post-marketing only, or belong to other products, so none can represent its own clinical progression.
Also in development:Ulcerative Colitis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
83 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 82 same-indication; 69 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Omilancor: this drug | Phase 2 | Small molecule | LANCL2 | ||
| NIM-1324 | Phase 1 | Small molecule | LANCL2 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha | ||
| Adalimumab-Aqvh (Yusimry) | Approved | — | TNF-alpha | ||
| Adalimumab-Atto (Amjevita) | Approved | — | TNF-alpha | ||
| Adalimumab-Bwwd (Hadlima) | Approved | — | TNF-alpha | ||
| Adalimumab-Fkjp (Hulio) | Approved | — | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Balsalazide Disodium (Colazal) | Approved | — | Aminosalicylate | ||
| Balsalazide Disodium (Giazo) | Approved | — | Aminosalicylate | ||
| Budesonide (Entocort EC) | Approved | — | Glucocorticoid receptor |
…and 68 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.